Data-driven weight management

The science of weight loss,
made personal

An independent GLP-1 safety database. Real data from clinical trials, patient experiences, and regulatory reports — free, with every source cited.

Explore the data Join the waitlist
2,969 data points
15 effects tracked
Updated daily

2,969

Data points

15

Effects tracked

9

Drugs covered

8

Data sources

Tools

Your personal journey

Side Effects Predictor

See your personalised risk profile for 15 side effects

Try it

Weight Trajectory

Predict your weight loss journey from STEP, SURMOUNT and SCALE trial data

Try it

Muscle Preservation

Assess your risk of muscle loss and get evidence-based recommendations

Try it

After Stopping

Understand what happens when you stop — and how to prepare

Try it
Trending

What's happening in GLP-1

UK GLP-1 grey market: 135 companies, 1 death — what patients need to know

Our Companies House audit: 98 brand-new shell companies, no credible GLP-1 supplier, and documented harm.

Read more

Generic semaglutide in India after the March 2026 patent expiry

India's patent expiry opens the door for dozens of affordable generic versions.

Read more

CDSCO-approved generics bring weight management costs below ₹1,500/month

Registered generics make weight management accessible to millions.

Read more
How It Works

Four ways to use Magistra today

01

Explore the database

2,969 structured data points across 15 side effects and 9 medications — updated daily, sources cited.

02

Check your personal risk

The free predictor estimates your side-effect risks and weight trajectory from your profile.

03

Read the evidence

Clinical trials side by side with real-world reports, plus weekly market and pricing analysis by country.

04

Tell us what to track

Missing a side effect, drug, or data source? Your suggestions steer what we collect next.

Why Magistra

Three layers of safety, in one platform

Almost everything written about GLP-1 online comes from someone selling you something — the manufacturer, a clinic, or the grey market. We don't sell medication. We publish the data.

01

Independent, sells nothing

We don't prescribe, don't dispense, and earn nothing from your treatment — so our numbers have nothing to sell. Every data point carries its source: clinical trials, FDA FAERS, regulators, and patient reports. Methodology published in full.

Read the methodology
02

Data-powered predictions

An independent, fully cited GLP-1 safety and efficacy database — drawn from clinical trials, FDA FAERS, regulatory reports, and patient experiences. Personalised forecasts for weight loss, side effects, and muscle preservation, to take to your own doctor.

See your forecast
03

Global supply intelligence

Weekly-updated tracking of GLP-1 supply, demand, and pricing across major global markets — patent expiries, licensed generic launches, cross-market pricing, and what you can check yourself about a pack and its cold chain.

Explore the market
Blog

Latest articles

Science & Safety·5 min

A 12-Day Study and REWIND's 7-Year One Both Feed Our Pooled GLP-1 Nausea Rate — Here's How Much Each Counts

The trials behind our pooled rates tracked adverse events for anywhere from 1.7 to 364 weeks — 12 days to 7 years. As of 3 October 2026, 755 of the 1,671 eligible registry rows that state a counting window (45.2%) come from trials of 26 weeks or less, yet across seven tracked effects those short trials carry 1.1–2.4% of the pooled weight, not their row-count share. Nausea's own median stated rate is 8.0% in trials of 26 weeks or less and 25.2% in trials over two years — computed by the same windowMix function that runs on magistra.health, and checked against the live data store.

Read
Science & Safety·6 min

Tirzepatide vs Semaglutide 1 mg: One Trial Randomized 1,879 Patients and Cleared No Side-Effect Gap at the Corrected Bar

SURPASS-2 (NCT03987919) randomized 1,879 adults with type 2 diabetes on metformin to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg, open-label, for up to 44 weeks. Across six tracked side effects and three tirzepatide doses — 18 comparisons — the largest gaps were diarrhoea at 10 mg (+4.9 points, z=2.17) and reduced appetite at 15 mg (+3.6 points, z=2.15), both past the single-test line and short of the Bonferroni-corrected bar. No gap is established; two are suggestive. Every row read from the registry.

Read
Science & Safety·7 min

Orforglipron vs Oral Semaglutide: One Trial Randomized 1,698 Patients and Compared Eight Side Effects at Two Dose Levels

ACHIEVE-3 (NCT06045221) randomized 1,698 adults with type 2 diabetes on metformin between two daily GLP-1 tablets, orforglipron and oral semaglutide, at two dose levels for 52 weeks. At the low pair (12 vs 7 mg) orforglipron reported more nausea (26.4% vs 13.1%), vomiting (17.0% vs 7.7%) and diarrhoea (21.7% vs 13.1%), all three clearing a 16-test correction; at the high pair (36 vs 14 mg) no gap cleared it. Open-label and Lilly-funded. Every row read from the registry.

Read
For Researchers

For researchers and healthcare professionals

Access the GLP-1 Safety Database via our public API. Free for citations, subscription for bulk access.

Explore the API Contact us
API
curl magistra.health/api/data?q=overview
{
  "totalDataPoints": 2,969,
  "totalEffectsTracked": 15,
  "drugsTracked": ["semaglutide", "tirzepatide", "liraglutide", ...],
  "dataSources": [{ "source": "PubMed", "points": ... }, ...]
}

What you can do today

Magistra is a data source, not a clinic. Everything below is available right now, free and without an account.

See your risk profile

Side-effect risk, weight trajectory, muscle loss, and discontinuation outlook, fitted to your characteristics.

Explore the open database

2,969 data points, each carrying its source, with clinical and real-world rates kept separate.

Use the data in your own work

Free public API, citable dataset, and published methodology for researchers, analysts, and journalists.

Get notified about new data

The database grows daily. Leave your email and we'll write when a major dataset release or new finding lands. No medication sales.

See your personal GLP-1 side-effect risk

Free Predictor